Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Management of the refractory aplastic anemia patient: what are the options?

    ... refractory AA patients are fit and have a suitably matched donor, either a sibling (> 40-50 years) or unrelated donor . Patients lacking a fully matched donor should be ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)

    ... stem cell transplant (HSCT) from a matched sibling donor (MSD) is the treatment of choice. If a MSD is not available, the options include immunosuppressive therapy (IST) or unrelated donor HSCT. The objective of this guideline is to provide ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation

    ... S, Lackner H, Müller E, Schwinger W. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention ... refractory AAA without a MSD underwent HSCT from matched unrelated (n = 6) or haploidentical (n = 1) donors. Conditioning ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research

    ... (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Blood stream infection after stem cell transplantation in children with idiopathic aplastic anemia

    ... therapy with anti-thymocyte globulin, transplantation from unrelated donors, frequent blood transfusion before transplantation, ... in patients who were transplanted from an unrelated donor , control of BSI is very important for success of HSCT in patients ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network.

    ... should be developed; (4) innovative approaches to unrelated donor BMT that decrease graft-versus-host disease are needed; and (5) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    ... donors were HLA -identical (22 siblings and one unrelated) and 3 were HLA-mismatched (2 related and one unrelated). ... and cyclophosphamide (in all cases from identical donor) and 11 were given a reduced intensity conditioning (8 from identical ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Transplantation strategies for the management of patients with myelodysplastic syndromes.

    ... CST replaces recipient dysplastic hemopoiesis with healthy donor haemopoiesis and immune system with an attendant graft-versus-leukemia ... in patients with high-risk MDS. Allogeneic SCT from matched unrelated donors produce poorer results than matched related siblings' ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Clinical management of aplastic anemia.

    ... of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and ... to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes - Lingering Uncertainties and Emerging Possibilities

    ... conditioning (RIC) regimens, increased availability of unrelated donors, new donor sources and improvements in transplant technology and supportive ...

    Research Article last updated 07/20/2018 - 5:15pm.